Familial defective apo B-100 (FDB), 106t, 107

Familial disorders of triglyceride metabolism, 107

Familial dysbetalipoproteinemia, 106t, 107

Familial hypercholesterolemia (FH), 106–107, 106t

Familial hypertriglyceridemia (FHTG), 107

FAP (see Functional abdominal pain (FAP))

FAST HUG checklist, 1206

FASTHUG-MAIDENS checklist, 1206

Fasting blood glucose (FBG), 1097

Fasting plasma glucose (FPG), 1076, 1082

Fat

diabetes and, 1080

in enteral formulas, 779

Fatigue and MS, 1223–1224

FBG (see Fasting blood glucose (FBG))

FCHL (see Familial combined hyperlipidemia (FCHL))

FDA (see Food and Drug Administration (FDA))

FDA Adverse Event Reporting System (FAERS), 328

FDB (see Familial defective apo B-100 (FDB))

Febrile neutropenia, 1972

Febrile seizures, 1294–1295, 2157

Fecal antigen test, 492, 492t

FENa

(see Fractional excretion of sodium (FENa

))

Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diets, 534

Fetal bradycardia, 986

Fetal hypothyroidism, 1064–1065

Fetal organogenesis, 968

Fetal tachycardia, 996

Fetomaternal hemorrhage, 998–999

FEV (see Forced expiratory volume (FEV))

Fever, 2156–2157

drug, 688–690, 690t

infection and, 1322

Fever of unknown origin (FUO), 1322

FH (see Familial hypercholesterolemia (FH))

FHTG (see Familial hypertriglyceridemia (FHTG))

Fiber, in polymeric formulas, 774–775

Fiber-optic upper endoscopy, 493

Fibrinogen, role of, 175

Fibroblast growth factor 23 (FGF23), 618

Fibromyalgia, 1192–1194, 1193f, 1194t

Fine needle aspiration (FNA), 1043

Fingertip unit (FTU) concept, 817–818, 817t

Fish oils, 779

Flat worms (see Cestodiasis (tapeworm infection))

Flexural/inverse psoriasis, 833 (see also Psoriasis)

Fluid and electrolyte maintenance, 2139–2143, 2140–2141t

administration of, 2141–2142

balance

ascites, 542–543

sodium restriction, 542

urinary NA:K ratio, 542

vasopressin (V2) receptor antagonists, 542–543

water restriction, 542

calculation of, 2139

and CKD

electrolyte and metabolic disturbances, 611

hyperkalemia, 610–611

metabolic acidosis, 611

sodium and water retention, 610

complications

electrolyte and metabolic disturbances, 611

hyperkalemia, 610–611

metabolic acidosis, 611

sodium and water retention, 610

Fluids

EN and, 776

hypernatremia and, 22

removal of, 660

FNA (see Fine needle aspiration (FNA))

Foam cells, 108, 109f

Focal segmental glomerulosclerosis (FSGS), 628–629

FODMAPs diets (see Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols

(FODMAPs) diets)

Folic acid, 1099

antagonists, 1954t

deficiency anemia, 1936–1938

and pregnancy, 968, 969, 979

recommended daily allowance (RDA), 969

and women, 969

Follicle-stimulating hormone (FSH), 958, 1028

Food and Drug Administration (FDA), 36, 71, 80, 81, 168, 178, 214, 579, 643, 1363, 1840

guidelines for theophylline dosing, 398t

and pregnancy, 974

Forced expiratory volume (FEV), 379, 383

Forced expiratory volume in 1 second (FEV1

), 451–452, 455, 460

Forced vital capacity (FVC), 411

Formulas

for EN, 771–775, 772t

immune-modulating, 779

oligomeric, 771, 773

polymeric, 771

specialized, 773–775

Foscarnet-resistant HSV, 1651

4-T score, role of, 185

FPG (see Fasting plasma glucose (FPG))

FPS (see Faces pain scale (FPS); Functional pain syndromes (FPS))

Fractional excretion of sodium (FENa

), 637

Francisella tularensis, 1723

Frank–Starling curve, 267, 268f

FRC (see Functional residual capacity (FRC))

Free phenytoin levels, 55f

French Pharmacovigilance Database, 49

Fresenius dialyzer, 654

Fructosamine, 1083

FSGS (see Focal segmental glomerulosclerosis (FSGS))

FSH (see Follicle-stimulating hormone (FSH))

FTU concept (see Fingertip unit (FTU) concept)

Fulminant hepatitis, 1664

Fulminant RMSF, 1725

F

u

n

c

t

i

o

n

a

l

a

b

d

o

m

i

n

a

l

p

a

i

n

(

F

A

P

)

,

1

1

9

4

–

1

1

9

5

s

ymp

t

o

m

-

r

e

la

t

e

d

b

e

h

a

v

io

r

s

o

f,

1

1

9

5

t

tr

e

a

tme

nt

o

f,

1

1

9

5

F

u

n

c

t

i

o

n

a

l

d

y

s

p

e

p

s

i

a

,

4

8

6

F

u

n

c

t

i

o

n

a

l

p

a

i

n

s

y

n

d

r

o

m

e

s

(

F

P

S

)

,

1

1

9

2

–

1

1

9

7

F

u

n

c

t

i

o

n

a

l

r

e

s

i

d

u

a

l

c

a

p

a

c

i

t

y

(

F

R

C

)

,

3

8

3

F

u

n

g

a

l

e

n

d

o

c

a

r

d

i

t

i

s

,

1

3

9

9

–

1

4

0

0

F

u

n

g

a

l

i

n

fe

c

t

i

o

n

s

(

s

e

e

M

y

c

o

t

i

c

(

fu

n

g

a

l

)

i

n

fe

c

t

i

o

n

s

)

F

u

n

g

a

l

p

e

ri

t

o

n

i

t

i

s

,

1

4

7

6

–

1

4

7

7

F

U

O

(

s

e

e

F

e

v

e

r

o

f

u

n

k

n

o

wn

o

ri

g

i

n

(

F

U

O

)

)

F

VC

(

s

e

e

F

o

r

c

e

d

v

i

t

a

l

c

a

p

a

c

i

t

y

(

F

VC

)

)

GGA

D

(

s

e

e

G

e

n

e

r

a

l

i

z

e

d

a

n

x

i

e

t

y

d

i

s

o

r

d

e

r

(

GA

D

)

)

p. 2

3

3

9

p. 2

3

4

0

G

a

i

n

-

o

ffu

n

c

t

i

o

n

g

e

n

e

m

u

t

a

t

i

o

n

,

1

0

7

G

a

l

a

c

t

o

r

r

h

e

a

,

1

0

4

1

t

G

a

l

l

b

l

a

d

d

e

r

d

i

s

e

a

s

e

,

2

2

7

6

a

n

d

p

o

s

tme

n

op

a

u

s

a

l

h

o

r

mo

n

e

th

e

r

a

p

y

,

1

0

3

1

t

G

a

l

l

s

t

o

n

e

s

,

4

5

4

(

s

e

e

a

l

s

o

H

e

p

a

t

i

c

i

n

v

o

l

v

e

m

e

n

t

,

i

n

c

y

s

t

i

c

fi

b

r

o

s

i

s

)

γ

-

a

m

i

n

o

b

u

t

y

ri

c

a

c

i

d

,

5

5

2

G

a

m

m

a

-

g

l

u

t

a

m

yl

t

r

a

n

s

fe

r

a

s

e

(

G

G

T

)

,

3

0

b

lo

o

d

c

h

e

mis

tr

y

r

e

fe

r

e

n

c

e

v

a

lu

e

s

fo

r

,

1

9

t

G

a

r

d

n

e

r

e

l

l

a

v

a

g

i

n

a

l

i

s

,

9

9

1

G

a

s

t

ri

c

a

c

i

d

s

e

c

r

e

t

o

ry

s

t

u

d

i

e

s

,

4

9

2

G

a

s

t

ri

c

c

a

n

c

e

r

,

4

9

3

G

a

s

t

ri

c

e

m

p

t

yi

n

g

,

5

0

4

G

a

s

t

ri

c

l

av

a

g

e

,

6

6

G

a

s

t

ri

n

,

4

8

2

G

a

s

t

r

o

d

u

o

d

e

n

a

l

s

u

r

g

e

ry

,

p

r

o

p

h

yl

a

x

i

s

fo

r

,

1

3

4

5

t

G

a

s

t

r

o

e

s

o

p

h

a

g

e

a

l

r

e

fl

u

x

d

i

s

e

a

s

e

(

GE

R

D

)

,

4

5

3

,

2

1

6

1

–

2

1

6

4

,

2

1

6

3

t

a

nt

ir

e

flux

s

ur

g

e

r

y

,

5

1

1

c

linic

a

l

a

s

s

e

s

s

me

nt

a

n

d

dia

gn

o

s

is

,

5

0

6–

5

0

7

a

c

id

s

upp

r

e

s

s

io

n

e

mp

ir

ic

t

e

s

t

,

5

0

6–

5

0

7

a

mb

ula

t

o

r

y

p

H

mo

nit

o

r

in

g

,

5

0

7

e

s

op

h

a

g

e

a

l

ma

n

o

me

tr

y

,

5

0

7

r

a

dio

lo

g

ic

t

e

s

t

in

g

,

5

0

7

upp

e

r

e

n

do

s

c

op

y

a

n

d

b

iop

s

y

,

5

0

7

c

linic

a

l

p

r

e

s

e

nt

a

t

io

n

o

f,

5

0

4

,

2

1

6

2

e

p

id

e

mio

lo

gy

,

5

0

2

–

5

0

3

e

t

io

lo

gy

a

n

d

r

is

k

fa

c

t

o

r

s

,

5

0

3

e

xtr

a

e

s

op

h

a

g

e

a

l

ma

nife

s

t

a

t

io

n

s

,

5

0

9

–

5

1

1

,

5

1

0

t

ma

int

e

n

a

n

c

e

th

e

r

a

p

y

,

5

0

9

ma

n

a

g

e

me

nt

o

f,

5

0

6

f

n

o

n

e

r

o

s

iv

e

r

e

flux

dis

e

a

s

e

,

5

0

9

o

n

-

d

e

ma

n

d

p

h

a

r

ma

c

o

th

e

r

a

p

y

,

5

0

9

p

a

th

op

hy

s

io

lo

gy

,

5

0

3

–

5

0

4

p

h

a

r

ma

c

o

th

e

r

a

p

y

,

5

0

8

–

5

0

9

P

P

I

a

n

d

H

2

RA

s

,

5

0

9

tr

e

a

tme

nt

,

5

0

4–

5

0

6

,

2

1

6

2

–

2

1

6

4

,

2

1

6

3

t

G

a

s

t

r

o

i

n

t

e

s

t

i

n

a

l

c

o

m

p

l

i

c

a

t

i

o

n

s

,

6

2

4